2021 American Transplant Congress
Management of Drug Interactions During Protocolized Implementation of Posaconazole Immediately Post Heart Transplant
Massachusetts General Hospital, Boston, MA
*Purpose: Posaconazole (POSA) is a strong CYP3A4 inhibitor known to increase tacrolimus exposure by up to 4-fold. Initiation requires empiric tacrolimus dose adjustment and close…2021 American Transplant Congress
Unquantified Blips Lead to CMV Slips – Post Transplant CMV Monitoring in High Risk Kidney Transplant Recipients
*Purpose: Cytomegalovirus (CMV) is a significant cause of morbidity, mortality, and graft failure after solid organ transplantation, with high risk (D+/R-) patients being the highest…2021 American Transplant Congress
Impact of a Cmv Cell Mediated Immunity Based Protocol on Guiding Cmv Prophylaxis Following Pediatric Liver Transplantation – A Single Center Experience
*Purpose: Cytomegalovirus (CMV) is an important cause of morbidity following pediatric orthotopic liver transplantation (OLT), especially among high risk (HR) CMV D+/R- recipients. In 2019,…2021 American Transplant Congress
Discontinuation of Trimethoprim/sulfamethoxazole Prophylaxis Due to Hyperkalemia in Kidney Transplant Recipients
*Purpose: Trimethoprim-sulfamethoxazole (TMP-SMX) is the drug of choice for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in kidney transplant recipients (KTRs), however, it can be complicated by…2021 American Transplant Congress
Evaluating Pneumocystis Jiroveci Pneumonia Prophylaxis in Lung Transplant Recipients
Michigan Medicine, Ann Arbor, MI
*Purpose: The incidence of Pneumocystis jiroveci pneumonia (PJP) in lung transplant recipients (LTRs) on PJP prophylaxis is not well documented yet reported as high as…2021 American Transplant Congress
An Unusual Viral Tropism in a Solid Organ Transplant Recipient
*Purpose: Cytomegalovirus (CMV) tissue-invasive disease occurs in higher proportion in CMV-mismatched kidney transplant recipients (KTxR) with no pre-existing immunity and those who are markedly immunologically-impaired.…2021 American Transplant Congress
De Novo Hepatitis B Infection Following Liver Transplant with Hepatitis B Core Antibody Positive Graft
*Purpose: The risk of de novo HBV infection in liver transplant recipients of Hepatitis B core antibody (HBcAb) positive donor organs is tempered by availability…2021 American Transplant Congress
Incidence of Oral Candidiasis in Renal and/or Pancreas Transplant Recipients When Administering Prophylaxis versus No Prophylaxis
*Purpose: Oropharyngeal candidiasis (OC), or thrush, is a fungal infection associated with immunosuppression post renal and or/pancreas transplant. Currently, the role of prophylactic oral nystatin…2021 American Transplant Congress
Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…2021 American Transplant Congress
Cost-Effectiveness Analysis of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 14
- Next Page »